Search

Aim: Primary vaginal cancer is rare, comprising about 3% of all gynaecological malignancies. Solitary bone metastases to appendicular skeleton are extremely rare and there are only few published reports. We report the case of isolated metastasis in the tibia as a feature of primary squamous vaginal carcinoma. We present this case because of its rarity and for documentation and discussion purposes. Case report: We present a case of a 44-year old woman diagnosed with squamos vaginal cancer in June 2015. Computed tomography of the thorax, abdomen and pelvis revealed no distant metastases. She was treated with interstitial intracavitary brachytherapy and concomitant chemoradiotherapy. In March 2016 she was admitted to our hospital because of the swelling and the pain in the lower right leg. There was no history of trauma and plain radiographs were normal. Two months later, after further progression of pain, plain radiographs showed intramedullary permeative bone lesion with cortical disruption of tibial dyaphisis and local soft tissue swelling. MRI and core needle biopsy confirmed vaginal cancer metastasis containing tumor cells identical to the primary tumor. The patient was treated with radiotherapy and chemotherapy. Despite the treatment there was further progression of the disease with multiple bone metastases and eventually lung and brain metastases. Conclusion: This case report is another reminder that although extremely rare, solitary metastatic bone lesions of vaginal cancer are possible. Since symptoms mimic various benign conditions, it is important to consider bone metastasis as possible diagnosis in patients with progressive bone pain not responding to analgesic treatment. [ABSTRACT FROM AUTHOR]

Breast carcinoma is the most common malignant disease in the female and one of the leading causes of death among women worldwide. Chronic inflammation and immunosuppressive environment achieved by the interaction of tumour and infiltrating immune cells are the hallmarks of cancers, including breast cancer. Natural killer cells are one of innate immune cells in tumour bed that possess great antitumour potential due to their ability to kill tumour cells without prior sensitization. They also play an important role in priming of type I immune responses and are considered to be main source of Interferon-γ. Unfortunately, antitumour activity of natural killer cells is often suppressed by proinflammatory cytokines secreted in tumour microenvironment and suppression of NK cells activity often correlates with therapy response and general outcome of patient with breast carcinoma. Different types of breast cancer are associated with different subsets of natural killer cells that possess different immunoregulatory function. Identification of specific tumour associated natural killer cell subset endowed with different functional capabilities might help practitioners in therapy decisions, therapy response monitoring, as well as in predicting overall prognosis of breast cancer patients. The purpose of this review is to give an overview of natural killer cells and their subsets, their role in pathogenesis of breast cancer and to discuss NK cells as potential useful therapy and prognostic tool for breast carcinomas. [ABSTRACT FROM AUTHOR]